Your browser doesn't support javascript.
loading
Impact of SGLT2 Inhibitors on Very Elderly Population with Heart Failure with Reduce Ejection Fraction: Real Life Data.
Balaguer Germán, Jorge; Cortés García, Marcelino; Rodríguez López, Carlos; Romero Otero, Jose María; Esteban Chapel, Jose Antonio; Bollas Becerra, Antonio José; Nieto Roca, Luis; Taibo Urquía, Mikel; Pello Lázaro, Ana María; Tuñón Fernández, José.
Afiliación
  • Balaguer Germán J; Cardiology Department, Fundacion Jimenez Diaz Universitary Hospital, 28040 Madrid, Spain.
  • Cortés García M; Cardiology Department, Fundacion Jimenez Diaz Universitary Hospital, 28040 Madrid, Spain.
  • Rodríguez López C; Cardiology Department, Fundacion Jimenez Diaz Universitary Hospital, 28040 Madrid, Spain.
  • Romero Otero JM; Cardiology Department, Fundacion Jimenez Diaz Universitary Hospital, 28040 Madrid, Spain.
  • Esteban Chapel JA; Cardiology Department, Fundacion Jimenez Diaz Universitary Hospital, 28040 Madrid, Spain.
  • Bollas Becerra AJ; Cardiology Department, Fundacion Jimenez Diaz Universitary Hospital, 28040 Madrid, Spain.
  • Nieto Roca L; Cardiology Department, Son Spases Universitary Hospital, 07120 Palma, Spain.
  • Taibo Urquía M; Cardiology Department, Fundacion Jimenez Diaz Universitary Hospital, 28040 Madrid, Spain.
  • Pello Lázaro AM; Cardiology Department, Fundacion Jimenez Diaz Universitary Hospital, 28040 Madrid, Spain.
  • Tuñón Fernández J; Cardiology Department, Fundacion Jimenez Diaz Universitary Hospital, 28040 Madrid, Spain.
Biomedicines ; 12(7)2024 Jul 07.
Article en En | MEDLINE | ID: mdl-39062080
ABSTRACT
(1)

Background:

The validation of new lines of therapy for the elderly is required due to the progressive ageing of the world population and scarce evidence in elderly patients with HF with reduced ejection fraction (HFrEF). The purpose of our study is to analyze the effect of SGLT2 inhibitors (SGLT2i) in this subgroup of patients. (2)

Methods:

A single-center, real-world observational study was performed. We consecutively enrolled all patients aged ≥ 75 years diagnosed with HFrEF and for treatment with SGLT2i, and considered the theoretical indications. (3)

Results:

A total of 364 patients were recruited, with a mean age of 84.1 years. At inclusion, the mean LVEF was 29.8%. Median follow-up was 33 months, and there were 122 deaths. A total of 55 patients were under SGLT2i treatment. A multivariate Cox logistic regression test for all-cause mortality was performed, and only SGLT2i (HR 0.39 [0.19-0.82]) and glomerular filtration rate (HR 0.98 [0.98-0.99]) proved to be protective factors. In parallel, we conducted a propensity-score-matched analysis, where a significant reduction in all-cause mortality was associated with the use of SGLT2i treatment (HR 0.39, [0.16-0.97]). (4)

Conclusions:

Treatment with SGLT2i in elderly patients with HFrEF was associated with a lower rate of all-cause mortality. Our data show that SGLT2i therapy could improve prognosis in the elderly with HFrEF in a real-world study.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Biomedicines Año: 2024 Tipo del documento: Article País de afiliación: España Pais de publicación: Suiza

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Biomedicines Año: 2024 Tipo del documento: Article País de afiliación: España Pais de publicación: Suiza